Dr Jane Osbourn OBE FMedSci
CSO Alchemab Therapeutics
Alchemab Therapeutics
Elected Fellow 2021
Antibody engineering, immunology, biologics drug discovery and development
Jane Osbourn is CSO of Alchemab Therapeutics and her contribution to medical sciences has been to generate antibody-based medicines in the Biotech and Pharma industry. She contributed to the discovery and development of 8 approved drugs with all the subsequent benefits to human health.
Her work at Cambridge Antibody Technologies contributed to the invention of Humira, Benlysta and Abthrax before becoming a key member of the MedImmune team that delivered Durvalumab, Moxetumumab, Broadalumab, Benralizumab and influenza vaccines to the market.
She continues to pioneer new antibody-based medicines and is the scientific founder of a biotech company taking an entirely novel approach to find naturally-occurring protective antibodies and developing them as therapeutics.